D-1364-2019 Class II Terminated

Recalled by Torrent Pharma Inc — Levittown, PA

FDA drug recall D-1364-2019 was initiated by Torrent Pharma Inc on May 21, 2019 and is designated Class II. Reason for recall: cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii). The recall status is terminated (terminated Oct 6, 2020). Affected quantity: 6,000 bottles.

Recall details

Product Type
Drugs
Report Date
Jun 19, 2019
Initiation Date
May 21, 2019
Termination Date
Oct 6, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
6,000 bottles

Product description

Guaifenesin DAC Oral Solution, Sugar free, (Guaifenesin, Pseudoephedrine HCl and Codeine Phosphate Oral Solution, USP), Expectorant, Nasal Decongestant, Cough Suppressant, 100 mg/30 mg/10 mg per 5 mL, One Pint (473 mL) bottle, NDC: 16571-301-16, Manufactured by Bio-Pharm Inc., Levittown, PA 19057, Distributed by Rising Pharmaceuticals Inc., Allendale, NJ 07401.

Reason for recall

cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Distribution pattern

Product was distributed to 9 distributors, direct accounts and relabelers who may have further distributed the product throughout the United States.

Code information

Lot #s: 17E031, Exp. 05/2019; 18F030, Exp. 06/2020.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1364-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1364-2019. Report a data issue: hello@regdatalab.com.